Advertisement

Topics

Latest "Extab Corporation" News Stories

04:52 EDT 27th April 2018 | BioPortfolio

Here are the most relevant search results for "Extab Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Extab Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Extab Corporation for you to read. Along with our medical data and news we also list Extab Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Extab Corporation Companies for you to search.

Showing "Extab Corporation" News Articles 1–25 of 277

Relevant

CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation

IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, based upon the final vote count for the Company’s Special Meeting of Stockholders held today, a majority of its stockholders ...


Orion Corporation: Managers' transactions - Liisa Hurme

ORION CORPORATION         MANAGERS' TRANSACTIONS 2nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated pe...

Orion Corporation: Managers' transactions - Westerlund Riikka

ORION CORPORATION         MANAGERS' TRANSACTIONS 27 DECEMBER 2017 at 9.45 EET Orion Corporation: Managers' transactions - Westerlund Riikka Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associa...


Orion Corporation: Managers' transactions - Huhta-Koivisto Eemeli

ORION CORPORATION         MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 17.15 EET              Orion Corporation: Managers' transactions - Huhta-Koivisto Eemeli Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by...

Orion Corporation: Managers' transactions - Huhta-Koivisto Kalle

ORION CORPORATION   MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 15.50 EET Orion Corporation: Managers' transactions - Huhta-Koivisto Kalle Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated p...

Orion Corporation: Managers' transactions - Huhta-Koivisto Tero

ORION CORPORATION      MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 16.00 EET Orion Corporation: Managers' transactions - Huhta-Koivisto Tero Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associa...

Orion Corporation: Managers' transactions - Ylppö Jukka

ORION CORPORATION         MANAGERS' TRANSACTIONS 03 JANUARY 2018 at 15.10 EET              Orion Corporation: Managers' transactions - Ylppö Jukka Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and t...

Orion Corporation: Managers' transactions - Huhta-Koivisto Esko kuolinpesä

ORION CORPORATION      MANAGERS' TRANSACTIONS 18 DECEMBER 2017 at 15.45 EET              Orion Corporation: Managers' transactions - Huhta-Koivisto Esko kuolinpesä Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made b...

Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018

ORION CORPORATION         STOCK EXCHANGE RELEASE         1 MARCH 2018   at 19.10 EET             Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018 In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2018  transferred altogether 112,961 Orion Corporation B shares held by...

Stryker declares a $0.47 per share quarterly dividend

Kalamazoo, Michigan - February 7, 2018 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.47 per share payable on April 30, 2018 to shareholders of record at the close of business on March 29, 2018, representing an increase of approximately 11% versus the prior year and unchanged from the previous quarter.  Stryker is on...

Crown Bioscience Announces Merger with JSR Corporation

SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced yesterday that they will merge with and become a fully owned sub...

Vestaron Corporation is Named in the 2018 Global Cleantech 100

KALAMAZOO, Mich., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Vestaron Corporation, a leading developer of peptide-based bioinsecticides, today announced it was named in the prestigious 2018 Global Cleantech 100, produced by CTG (Cleantech Group), whose research and events services keep its audiences and clients in touch with emerging trends, leading innovation companies and all key players in sustaina...

Andrew Read to Join Board of Directors of International Endeavors Corporation

TEMECULA, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--- International Endeavors Corporation, a Medical Marijuana IP Holdings Company today announced that Andrew Read has agreed to join the company’s Board of directors. Read most recently served as president of Voltage River, a boutique energy services company providing energy management solutions to businesses and home owner...

Advanced Proteome Therapeutics and ImmunoBiochem Corporation enter into a Collaboration and Option Agreement

VANCOUVER, British Columbia and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates.  The companies will evaluate the prospect of combining ImmunoBiochem’s pr...

ImmuCell Corporation Announces Pricing of $3 Million Public Offering of Common Shares

PORTLAND, Maine, Dec. 19, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (“ImmuCell” or the “Company”) (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced an underwritten public offering of 417,807 shares of common stock at a...

ImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock

PORTLAND, Maine, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ImmuCell Corporation (“ImmuCell” or the “Company”) (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the closing of a previously announced underwritten public offering o...

Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices

EAST RUTHERFORD, N.J., April 19, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices.  Cambrex’s commitment to the environment, ...

International Stem Cell Corporation is Valued at $33 Million Market Value by Edison Investment Research

CARLSBAD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued at $33 million, up from $27 million in May 2017, by Edison Investment Research (“Edison”), a world-...

International Stem Cell Corporation Announces 2017 Fourth Quarter and Year-End Results

CARLSBAD, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period en...

International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease

CARLSBAD, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported today that a third patient of the second cohort with Parkinson's disease was successfully trans...

Stryker increases dividend 11%, declaring a $0.47 per share quarterly dividend

Kalamazoo, Michigan - December 6, 2017 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders of record at the close of business on December 29, 2017, representing an increase of approximately 11% versus the prior year and the previous quarter.  "Our financial st...

International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson's Disease Clinical Trial

CARLSBAD, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson's disease, was successfully transplanted wi...

International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017

CARLSBAD, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ending o...

Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events

MENLO PARK, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2017 and recent events. Fourth Quarter and Year-End 2017 Results For the fourth quarter of 2017, the company reported a net loss of $7.4 million, or $0.05 per share, compared to $8.5 million, or $0.05 per share, for the c...

AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.

LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, and XOMA Corporation (“XOMA”) (NASDAQ:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, announ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks